852 Winter Street
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com .
Richard F. Pops- Chairman and Chief Executive Officer
Shane Cooke- President
Kathryn L. Biberstein- Executive Vice President, Chief Compliance Officer and Chief Administrative Officer, and Secretary Alkermes plc
Iain Brown- Senior Vice President, Finance and Chief Accounting Officer
Madeline D. Coffin- Senior Vice President, Human Resources
Elliot W. Ehrich, M.D.- Executive Vice President, Research and Development
James M. Frates- Senior Vice President, Chief Financial Officer
David J Gaffin- Senior Vice President, Chief Legal Officer
Georgianna Harris, Ph.D.- Senior Vice President, Regulatory Affairs
Craig Hopkinson, M.D.- Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs
Blair C. Jackson- Senior Vice President, Business Development
Michael J. Landine- Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.- Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman- Vice President, Government Affairs and Policy
Declan O’Connor- Senior Vice President, Operations
Phil Shanahan, Ph.D.- Vice President, Quality Operations
Mark P. Stejbach- Senior Vice President, Chief Commercial Officer
Alkermes Corporate Headquarters
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Co Westmeath, Ireland
+353 90 649 5000
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
616 articles with Alkermes
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
- Updated Data From ARTISTRY Clinical Program Highlight Anti-Tumor Activity as Monotherapy and in Combination With Pembrolizumab - - Data Support Advancement of Regulatory Strategy in Cancers With High Unmet Need - - Company to Host Investor Webcast Today at 4:00 p.m. ET -
Alkermes plc announced that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET.
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
Alkermes plc announced that the U.S. Food and Drug Administration has approved LYBALVI™ for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.
The U.S. FDA is starting off the summer months with a busy week after the Memorial Day holiday in the U.S. Here’s a look.
The newly approved drug, Lybalvi, is a once-daily oral antipsychotic drug that is both a maintenance monotherapy or for the acute treatment of manic or mixed episodes.
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva , to the company's Board of Directors ("Board"). Emily Peterson Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies. A former Lazard M&A Partner with more than 15 years of banking experience
Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants ® program beginning on May 20, 2021 .
Alkermes plc announced that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 2:45 p.m. ET.
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May.
5/3/2021Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Alkermes plc (Nasdaq: ALKS) today announced that it has reached an agreement with Sarissa Capital Management LP ("Sarissa Capital"), a beneficial owner of approximately 5% of the company's outstanding ordinary shares
-- First Quarter Revenues of $251.4 Million Reflect Solid Performance of VIVITROL® and ARISTADA® -- -- Achieves GAAP Loss per Share of $0.14 and Basic and Diluted Non-GAAP Earnings per Share of $0.11, Supported by Disciplined Expense Management -- -- Financial Expectations for 2021 Reiterated --
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
- Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa -
Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy.
There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Apr. 28, 2021 to discuss the company's first quarter 2021 financial results.
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -
Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer
Alkermes plc announced that it has entered into a clinical trial collaboration and supply agreement with MSD for a planned phase 3 study to evaluate nemvaleukin alfa, Alkermes' novel investigational engineered interleukin-2 variant immunotherapy, in combination with MSD's KEYTRUDA®, in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3 rd Annual CNS Day on Thursday, Apr. 1, 2021 at 8:30 a.m. ET ( 1:30 p.m. BST ). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Company Will Provide New Updates and Disclose New Programs in Neuroscience and Oncology Development Pipeline